Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.29 -0.3%	$3.68	$1.24 ▼ $4.08	$874.98M	0.96	3.90 million shs	2.89 million shs
GPCR Structure Therapeutics	$18.53 -3.3%	$19.52	$13.22 ▼ $45.37	$1.10B	-1.89	952,846 shs	402,760 shs
NMRA Neumora Therapeutics	$1.58 +1.3%	$1.30	$0.61 ▼ $17.19	$252.63M	2.91	1.76 million shs	597,502 shs
SYRE Spyre Therapeutics	$16.86 -3.1%	$16.26	$10.91 ▼ $40.26	$1.05B	2.82	516,100 shs	270,930 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-0.30%	+9.30%	-15.21%	+26.05%	+143.70%
GPCR Structure Therapeutics	-3.29%	+14.38%	-3.64%	-26.38%	-48.87%
NMRA Neumora Therapeutics	+1.28%	-4.24%	+8.97%	+125.71%	-85.85%
SYRE Spyre Therapeutics	-3.10%	+10.63%	+10.12%	+11.07%	-31.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.9854 of 5 stars	3.6	2.0	4.0	2.6	0.8	0.6
GPCR Structure Therapeutics	2.487 of 5 stars	3.5	3.0	0.0	1.4	1.7	0.6
NMRA Neumora Therapeutics	2.9322 of 5 stars	3.1	3.0	0.0	3.3	2.5	0.6
SYRE Spyre Therapeutics	3.1236 of 5 stars	3.6	2.0	0.0	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	105.17% Upside
GPCR Structure Therapeutics	3.00	Buy	$75.71	308.60% Upside
NMRA Neumora Therapeutics	2.22	Hold	$7.14	352.08% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	216.73% Upside

Current Analyst Ratings Breakdown

Latest NMRA, GPCR, SYRE, and AKBA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.45	N/A	N/A	$0.11 per share	29.91
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$13.40 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.13 per share	N/A
SYRE Spyre Therapeutics	$890K	1,144.21	N/A	N/A	$4.97 per share	3.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	N/A
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	N/A
NMRA Neumora Therapeutics	-$243.79M	-$1.57	N/A	N/A	N/A	N/A	-98.95%	-87.68%	N/A
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	N/A

Latest NMRA, GPCR, SYRE, and AKBA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	-$0.33	+$0.05	-$0.33	N/A	N/A
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
GPCR Structure Therapeutics	N/A	20.48	20.48
NMRA Neumora Therapeutics	0.11	10.54	10.54
SYRE Spyre Therapeutics	N/A	6.49	6.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
GPCR Structure Therapeutics	91.78%
NMRA Neumora Therapeutics	47.65%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
GPCR Structure Therapeutics	5.60%
NMRA Neumora Therapeutics	26.80%
SYRE Spyre Therapeutics	15.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.14 million	257.19 million	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
NMRA Neumora Therapeutics	108	161.95 million	118.54 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	51.08 million	Optionable

NMRA, GPCR, SYRE, and AKBA Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Brokerages

August 12 at 3:22 AM | marketbeat.com

XTX Topco Ltd Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 9, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from Wedbush

August 7, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

August 6, 2025 | marketbeat.com

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

TD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 2, 2025 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

August 1, 2025 | globenewswire.com

Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

July 28, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by Analysts

July 17, 2025 | marketbeat.com

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation

July 16, 2025 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Down 7.8% - Time to Sell?

July 15, 2025 | marketbeat.com

SYRE - Spyre Therapeutics Inc Trailing Returns - Morningstar

July 4, 2025 | morningstar.comM

Spyre Therapeutics Announces Grants of Inducement Awards

July 3, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

June 20, 2025 | theglobeandmail.com

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

June 18, 2025 | seekingalpha.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...

June 17, 2025 | finanznachrichten.de

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 17, 2025 | prnewswire.com

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

June 16, 2025 | prnewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards

June 6, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA, GPCR, SYRE, and AKBA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.29 -0.01 (-0.30%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.32 +0.02 (+0.76%)

As of 05:02 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Structure Therapeutics NASDAQ:GPCR

$18.53 -0.63 (-3.29%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$18.55 +0.02 (+0.11%)

As of 07:02 AM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Neumora Therapeutics NASDAQ:NMRA

$1.58 +0.02 (+1.28%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.02 (-0.95%)

As of 06:56 AM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$16.86 -0.54 (-3.10%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$16.21 -0.65 (-3.85%)

As of 04:12 AM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time